Share Name Share Symbol Market Type Share ISIN Share Description
Premaitha LSE:NIPT London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.15p +1.56% 9.75p 385,317 14:11:53
Bid Price Offer Price High Price Low Price Open Price
9.50p 10.00p 9.75p 9.60p 9.60p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 2.45 -12.12 6.00 1.6 37.7

Premaitha (NIPT) Latest News

More Premaitha News
Premaitha Takeover Rumours

Premaitha (NIPT) Share Charts

1 Year Premaitha Chart

1 Year Premaitha Chart

1 Month Premaitha Chart

1 Month Premaitha Chart

Intraday Premaitha Chart

Intraday Premaitha Chart

Premaitha (NIPT) Discussions and Chat

Premaitha (NIPT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-08-17 13:11:289.8075,0007,350.00O
2018-08-17 12:20:039.62504.81O
2018-08-17 12:03:559.6861,0005,904.80O
2018-08-17 12:03:559.6861,0005,904.80O
2018-08-17 10:43:589.6850,0004,838.00O
View all Premaitha trades in real-time

Premaitha (NIPT) Top Chat Posts

DateSubject
17/8/2018
09:20
Premaitha Daily Update: Premaitha is listed in the Software & Computer Services sector of the London Stock Exchange with ticker NIPT. The last closing price for Premaitha was 9.60p.
Premaitha has a 4 week average price of 7.55p and a 12 week average price of 7.15p.
The 1 year high share price is 10.30p while the 1 year low share price is currently 3.75p.
There are currently 386,843,523 shares in issue and the average daily traded volume is 1,163,789 shares. The market capitalisation of Premaitha is £37,717,243.49.
10/8/2018
12:53
theclangers: Is news anticipated soon? And what would it most likely be? Have NIPT tests now passed break even point and now making profits? Have noticed the share price is in ascendancy! I'm wondering what's the Driver?
09/8/2018
10:00
scotty1: If you're a subscriber and haven't seen it yet this piece yesterday about opti includes yet another mention about NIPT 😉 http://newsletters.advfn.com/hotstockrockets/4042/optibiotix-share-price-comment
14/7/2018
11:57
ngen yap: These are share options, so are not free. If directors choose to exercise, they have to pay 7.75p for them and company gets the funds. And assuming share price is above 7.75p, they earn the difference before tax. It is a very good incentivisation tool and I am not surprised (and pleased) they have been awarded, which gives directors added motivation to improve share price above 7.75p.
04/7/2018
20:22
twix386: Typical negative DaveGood news and share price reaction - oh dear!
26/6/2018
14:31
twix386: More good news.Share price hardly moves as usual.Bod, please give us the illumina closure news. Settlement or come out of UK. Other news is good or even great, but I don't much care anymore. The news that will propel us is and has always been closure on our never ending fiasco of litigation!!!!!!
11/6/2018
18:12
viking01: Illumina exposure is such a small part of group turnover and I suspect overseas news flow will continue and share price respond accordingly . Great opportunity to participate in what will be a great growth story
13/3/2018
22:00
slartybartfaster: The mouse is nailed again by his nemesis, elrico. Caught out in his double standards. elrico 13 Mar '18 - 19:25 - 2106 of 2108 0.000050 3 0 Michaelmouse answered while he still avoids the elephant in the room. MM: Firstly, why does it take them 5 months to prepare relatively simple accounts for the year ending in November 2017? To fill the void, surely they could issue a brief trading statement with guidance on revenues and cash remaining? Most reputable companies don't have a problem with this. Me: 3 months, 5 months, it matters not as long as they fall within the 6 month reporting limit. And you shouldn't use the word "reputable" when invested in frauds (AVN, INTQ) and a company that has restated accounts (TRAKM8). OPTI usually report interims within 4 months and FY 5 months. This info is on the company website, as has been pointed out before. MM:Secondly, by now after announcing a number of agreements they must have some idea about revenues for 2018? Me: Another double standard...lets keep it simple shall we, 7DIG, AVN, TRAKM8, IND, STL; have any of these given revenue guidance for the year ahead? If they have, I missed them. In any event, OPTI is barely 6 months (accounting calendar) into transition from R&D to commercial yet, and many of the partnerships are wrapped up in NDA's, which has attributed to the stagemation thus far. Surely you should be applauding the BOD for not ramping up their book, as so many AIM companies do. In any event, how do you quantify sales in new markets, with new products, using new science? Please explain! MM: Thirdly, the figures are really all that matter presently. At a market cap. of £50m, the potential has already been "baked in" to the share price and has been for two years. The figures they publish still need to justify the current market cap. never mind justify substantial gains in the share price Me: To a degree, I guess I can allow a little leeway with this opinion. However, I would point to the industry valuation for SweetBiotix of £20+m, just 1 of several possible spinouts, and it has no commercial footprint yet, no commercial partner that we know of yet. I would also point out OptiBiotic platform has recently enhanced the LGG strain, the world's most popular probiotic...I'll spare your blushes by not mentioning the value of this strain. OPTI have several strains, which has real potential to be significantly more valuable.....in time. In short, the IP has real value, especially those commercialised via SlimBiome and LP-LDL. MM: Anyway, it's aimho. On a more positive note, if you truly believe in the company and its potential then just hang on in there over the long term, but carefully monitor the figures because ultimately they will drive the share price. The rest is all speculation on what could or might be. Me: Ah, we are aligned. You have long advocated trusting your research and hold long term. And yes of course, one should always monitor what the company says, read between the lines and pay particular attention to companies accounts, especially those that are forced to restate profits as losses....cough, cough! MM: That's all from me for a while. Me: It's probably best, you made a hash of that and I suspect you are perhaps a little concerned the level of partnerships may well prove worthy of rewarding those of use that stand by our research, speak to the company and look at the humanbiome sector and see perhaps what others do not. Don't feel pressured to respond...It's best you don't - keep your head down. ;) http://uk.advfn.com/cmn/fbb/thread.php3?id=35291865&fast_access=1
12/2/2018
07:05
humphries1: Premaitha Health Plc ("Premaitha" or the "Company") Thermo Fisher - issue of warrants Manchester, UK - 12 February 2018 - Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces that further to the notification made 12 July 2017 it has issued the Second Tranche of warrants to Thermo Fisher Scientific ("Thermo Fisher"). Thermo Fisher has been issued a warrant over 12,417,368 ordinary shares in the Company which may be exercised at a price of 5.775 pence per share, being 10% over the closing share price on 8 February 2018. In aggregate Thermo Fisher now hold warrants over 95,688,706 ordinary shares, representing 21% of the Company on a fully diluted basis. The Company has no further contractual commitments to issue warrants to Thermo Fisher. Following the issue of the warrants above, the Company has warrants over 98,511,560 ordinary shares in issue, including those of Thermo Fisher. In addition the Company has options over 38,991,232 ordinary shares. The issued share capital of the Company comprises 321,218,279 Ordinary Shares of 0.1p each. The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014 and has been arranged for release by Barry Hextall, Chief Financial Officer of the Company.
20/10/2016
08:23
whites123: MAYA: Mayair Close to £5,500.000 still to spend on share buy back program. Averaged out that equates to over £1.40 per share, but all those bought lower means the upper price to pay can well exceed that marker. Tripling of the share price is easy once stock is in demand. Its a squeeze of epic proportions in the waiting. And yet another RNS from MAYA showing a further share buy back. Each and every time the rns comes out the price increases. Yesterday just 2 purchases. 1 from a PI buying 2,500 shares and the other purchase was a share buy back by the company. They have the mandate to buy approx a further 4 MILLION shares back. The share price will explode... Anyone else here excited about MAYA? (Mayair) They want to buy back 4,247,500 shares (10%) for a maximum of £5,755,750 They have already bought back 340,000 shares for £205,611 So they still have to buy back 3,907,500 shares with £5,550,139 They can pay up to 142p (£5,550,139 / 3,907,500) to acquire the outstanding stock but for every share they buy below 142p, they can pay more than 142p to complete the buy-back, so the price should keep stepping up. The objective of the buy back seems to be to get the share price up. This could triple from here. 19th Oct -2016 RNS today showing they bought back more shares.. In a lightly traded stock like this they have the mandate to buy back almost 4,000,000 more. Where will the share price be by then? Many many multiples of todays price is my best guess.
13/4/2015
13:24
the prophet: timmbo I agree with BlackSS, forget it, as it ain't going to add anything to £55m or whatever market cap NIPT. VIY didn't actually go bust, which was just as well, as it enabled Adam Reynolds to use VIY as a cash shell, but I know what you mean, BlackSS. For info, I think the IP is due to be returned to NIPT any day now, may even have happened. The focus is now clearly on NIPT, if there was any value in the IP, I'm sure Mr Reynolds will do what he can. imo, if we got £0.5m for it, that would be a bloody miracle. That would add, what, 0.25p onto the NIPT share price. That puts it in perspective! Move on is the best course of action, imo.
Premaitha share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180818 06:32:01